Dr. Matus Coma: Advancing Therapeutic Strategies in Pancreatic Cancer Research
Embedded Files
Dr. Matus Coma is a distinguished scientist from Slovakia, recognized for his impactful contributions to pharmacological research and cancer therapeutics. He will be a featured presenter at the 16th Emirates Pathology, Digital Pathology, Cancer Conference & Exhibition, a premier global forum that brings together leading experts in pathology, oncology, and biomedical research. Dr. Coma currently serves as a Leading Scientist in the Department of Pharmacology, Medical Faculty, Pavol Jozef Safarik University, where his research focuses on improving treatment outcomes through innovative drug-based strategies.
Dr. Coma will present a poster titled “Tigecycline Enhances the Cytotoxic Efficacy of FOLFIRINOX and Gem-Pac in Pancreatic Ductal Adenocarcinoma Cell Models” at the conference. This study explores novel therapeutic combinations aimed at enhancing the effectiveness of standard chemotherapy regimens for pancreatic ductal adenocarcinoma—one of the most aggressive and treatment-resistant malignancies. His work reflects the scientific depth and translational relevance showcased at the 16th EPUCG Conference & Exhibition.
Dr. Coma completed his PhD at Pavol Jozef Safarik University and has since built a strong academic and research profile. He has authored over 25 scientific publications in high-impact journals, with his work cited more than 300 times, and holds an H-index of 10. These achievements underscore his consistent contribution to advancing pharmacological and oncological sciences at an international level.
Research Interests
Research Interests
Dr. Coma’s primary research interests include pharmacology, anticancer drug mechanisms, chemotherapy optimization, combination therapies, and experimental cancer models, with a particular emphasis on pancreatic cancer treatment strategies.
Awards, Recognition, and Achievements
Awards, Recognition, and Achievements
Through his scholarly publications, citation impact, and leadership role at a leading medical faculty, Dr. Coma has earned recognition within the scientific community for his dedication to high-quality, impactful research. His work continues to influence ongoing studies in cancer pharmacology and therapeutic innovation.
Benefits of Attending
Benefits of Attending
Attendees will gain valuable insights into emerging pharmacological strategies for cancer treatment, learn about innovative drug combinations in pancreatic oncology, and engage with evidence-based research that supports future clinical applications. The conference also provides a unique opportunity to network with global experts, exchange interdisciplinary ideas, and stay informed about advancements shaping the future of pathology and cancer research.
To explore more about this global scientific platform, visit the official conference website at pathology.utilitarianconferences.com and learn about the upcoming 16th Emirates Pathology, Digital Pathology, and Cancer Conference & Exhibition at pathology.utilitarianconferences.com/16epucg2026. Researchers are encouraged to contribute their work via abstract submission at pathology.utilitarianconferences.com/submit-abstract.
To know more about Dr. Matus Coma, visit: https://pathology.utilitarianconferences.com/speaker/dr-matus-coma
Register Now: https://pathology.utilitarianconferences.com/registration
Conclusion
Conclusion
Dr. Matus Coma’s research exemplifies scientific rigor, innovation, and clinical relevance. His participation adds significant value to the conference, offering attendees an opportunity to engage with cutting-edge pharmacological research that addresses real-world challenges in cancer treatment. His work continues to inspire progress in oncology and reinforces the importance of collaborative scientific exchange.
Page updated
Google Sites
Report abuse